These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35286279)

  • 1. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study.
    Kim M; Kim H; Park S; Joo J; Kim IJ; Kim BH
    Eur J Endocrinol; 2022 Apr; 186(5):561-571. PubMed ID: 35286279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
    Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
    Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
    Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
    Marti JL; Jain KS; Morris LG
    Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
    Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
    Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
    Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
    Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
    Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
    J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
    J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
    Bhattacharyya N; Chien W
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
    Corrêa NL; de Sá LV; de Mello RC
    Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
    Nguyen NC; Anigati EM; Desai NB; Öz OK
    Semin Nucl Med; 2024 Jul; 54(4):488-496. PubMed ID: 38772827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
    Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary malignancies following thyroid cancer: a population-based study in Taiwan.
    Lu CH; Lee KD; Chen PT; Chen CC; Kuan FC; Huang CE; Chen MF; Chen MC
    Eur J Endocrinol; 2013 Nov; 169(5):577-85. PubMed ID: 23939917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
    Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
    Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
    Seo GH; Cho YY; Chung JH; Kim SW
    Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
    Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
    Wu W; Li S; Xu K; Meng Z
    Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study.
    Kim MS; Lee JW; Hyun MK; Song YS
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):288-299. PubMed ID: 38437824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
    Yang J; Wu F; An H; Gan H
    Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
    Subramanian S; Goldstein DP; Parlea L; Thabane L; Ezzat S; Ibrahim-Zada I; Straus S; Brierley JD; Tsang RW; Gafni A; Rotstein L; Sawka AM
    Thyroid; 2007 Dec; 17(12):1277-88. PubMed ID: 18020916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.